Bausch Health Companies reported disappointing first-quarter results, with revenue and earnings falling short of estimates. The company’s shares came under pressure as investors grappled with concerns over the future of its Xifaxan drug and the delayed monetization of its Bausch + Lomb stake. Management reaffirmed their full-year outlook, but analysts remained cautious due to the ongoing litigation and uncertainty surrounding the Bausch + Lomb separation.